Adverse pharmacokinetic interactions between illicit substances and clinical drugs

Kodye L. Abbott, Patrick C. Flannery, Kristina S. Gill, Dawn M. Boothe, Muralikrishnan Dhanasekaran, Sridhar Mani, Satyanarayana R. Pondugula

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Adverse pharmacokinetic interactions between illicit substances and clinical drugs are of a significant health concern. Illicit substances are taken by healthy individuals as well as by patients with medical conditions such as mental illnesses, acquired immunodeficiency syndrome, diabetes mellitus and cancer. Many individuals that use illicit substances simultaneously take clinical drugs meant for targeted treatment. This concomitant usage can lead to life-threatening pharmacokinetic interactions between illicit substances and clinical drugs. Optimal levels and activity of drug-metabolizing enzymes and drug-transporters are crucial for metabolism and disposition of illicit substances as well as clinical drugs. However, both illicit substances and clinical drugs can induce changes in the expression and/or activity of drug-metabolizing enzymes and drug-transporters. Consequently, with concomitant usage, illicit substances can adversely influence the therapeutic outcome of coadministered clinical drugs. Likewise, clinical drugs can adversely affect the response of coadministered illicit substances. While the interactions between illicit substances and clinical drugs pose a tremendous health and financial burden, they lack a similar level of attention as drug-drug, food-drug, supplement-drug, herb-drug, disease-drug, or other substance-drug interactions such as alcohol-drug and tobacco-drug interactions. This review highlights the clinical pharmacokinetic interactions between clinical drugs and commonly used illicit substances such as cannabis, cocaine and 3, 4-Methylenedioxymethamphetamine (MDMA). Rigorous efforts are warranted to further understand the underlying mechanisms responsible for these clinical pharmacokinetic interactions. It is also critical to extend the awareness of the life-threatening adverse interactions to both health care professionals and patients.

Original languageEnglish (US)
Pages (from-to)44-65
Number of pages22
JournalDrug Metabolism Reviews
Volume52
Issue number1
DOIs
StatePublished - Jan 2 2020

Keywords

  • CYP
  • Illicit substances
  • MDMA
  • adverse drug interactions
  • cannabis
  • cocaine
  • drug-metabolizing enzymes
  • drug-transporters

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Adverse pharmacokinetic interactions between illicit substances and clinical drugs'. Together they form a unique fingerprint.

  • Cite this

    Abbott, K. L., Flannery, P. C., Gill, K. S., Boothe, D. M., Dhanasekaran, M., Mani, S., & Pondugula, S. R. (2020). Adverse pharmacokinetic interactions between illicit substances and clinical drugs. Drug Metabolism Reviews, 52(1), 44-65. https://doi.org/10.1080/03602532.2019.1697283